ARQT vs BAC Stock Comparison
ARQT currently leads BAC in this stock comparison, with AIQ scores of 69 vs 58. The clearest difference is momentum, while BAC has the stronger risk resilience profile.
What is the main difference between ARQT and BAC?
ARQT leads the current stock comparison as Arcutis Biotherapeutics, Inc., with the clearest separation coming from momentum and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
Arcutis Biotherapeutics, Inc. vs Bank of America Corporation
ARQT leads
ARQT leads by 11 AIQ points, primarily on Momentum and Quality, and the lead has widened from 2 points over 30 sessions.
Competitive: 4 of 6 evidence groups support ARQT, its lead is widening, and its current signal state is conflicted.
Arcutis Biotherapeutics, Inc.
Bank of America Corporation
The Algovestiq AIQ Score currently favors ARQT over BAC, 69 versus 58 as of Nov 15, 2026. ARQT's advantage is driven primarily by stronger momentum and quality, while BAC holds the stronger risk resilience profile. ARQT also shows the stronger technical structure relative to its 50-day moving average. 4 of 6 covered evidence groups favor ARQT today, and the comparison is rated Competitive on stability: the leader is throwing conflicting signals. ARQT lead: Strengthening — the AIQ differential moved from 2 to 11 points over 30 sessions.
Compare Arcutis Biotherapeutics, Inc. and Bank of America Corporation across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Total return with distributions reinvested, from daily closes.
Total return comparison
Growth of $10,000, distributions reinvested
Split-adjusted closes; each distribution is reinvested at the close on its ex-dividend date. Taxes and trading costs are not modeled.
Compare ARQT and BAC against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Momentum76 vs 37ARQT +39
- Risk Resilience46 vs 83BAC +37
- Quality76 vs 64ARQT +12
- Value65 vs 68Even
4 of 6 evidence groups favor ARQT. ARQT’s edge is concentrated in momentum and quality; BAC keeps a meaningful risk resilience edge.
What changed since the last close
Latest scored session 2026-11-13, compared against the prior scored session 2026-11-12.
Largest factor move: Momentum -2
New signals
- ADX Trend Weakening — neutral, trend, medium horizon
- OBV Bullish Divergence — bullish, volume, medium horizon (-1.9%)
- Price Reclaimed 50-Day MA — bullish, trend, medium horizon
No factor moved materially.
New signals
- OBV Bullish Divergence — bullish, volume, medium horizon (-0.4%)
ARQT's lead narrowed by 1 AIQ point in the latest session.
Deeper signal detail for each name lives on its own signals page — ARQT and BAC both carry a full feed there.
The central trade-off
ARQT (Arcutis Biotherapeutics, Inc.): the stronger current systematic profile, led by momentum and quality.
BAC (Bank of America Corporation): the counter-case, on risk resilience.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
ARQTARQT on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
EvenGrowth figures are not covered for both names.
Value
EvenThe two are level on Value.
Momentum
ARQTARQT on the Momentum factor, by 39 points.
Lower downside
BACBAC on Risk Resilience, by 37 points.
Analyst upside
ARQTARQT on implied upside to the consensus price target.
AIQ vs Wall Street
Where the systematic read and the analyst consensus line up — and where they do not.
| Measure | ARQT | BAC | Note |
|---|---|---|---|
| Implied upside to target | +51.3% | +24.1% | ARQT has more room |
| Target dispersion | +21.1% | +25.3% | Lower is tighter analyst agreement |
| Consensus | Buy | Buy | Context, not a primary driver |
| Analysts covering | 8 | 25 | Higher coverage generally improves confidence |
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
4 of 6 covered evidence groups favor ARQT. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | ARQT | 69 vs 58 |
| Fundamentals | ARQTon balance | revenue growth 10.8% vs -3.3%; EPS growth -36.4% vs -23.8%; TTM ROE 3.6% vs 2.3%; gross margin 91.2% vs 60.4%; operating margin 6.9% vs 22.4% — ARQT takes 3 of 5 decided legs, not all of them |
| Valuation | Even | Value 65 vs 68 |
| Technicals | ARQT | Price vs 50-day 2.6% vs -5.6%; vs 200-day 11.4% vs -7% |
| Risk Resilience | BAC | Risk Resilience 46 vs 83 |
| Analyst expectations | ARQT | Target upside 51.3% vs 24.1% |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of ARQT and BAC and are excluded from the count.
AIQ Decision Stability
The two are close enough that your objective, not the score, should decide.
- The AIQ gap is moderate at 11 points.
- The leader's advantage has been widening. (supports the conclusion holding)
- The leader is throwing conflicting signals. (argues the conclusion is provisional)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on ARQT.
How the comparison changed
120 daily snapshots · May 27 – Nov 13ARQT lead: Strengthening — the AIQ differential moved from 2 to 11 points over 30 sessions.
- Today
- ARQT +11
- 69 vs 58
- 7 sessions ago
- ARQT +13
- 71 vs 58
- 30 sessions ago
- ARQT +2
- 64 vs 62
- 90 sessions ago
- BAC +8
- 63 vs 71
The lead changed hands 5 times in this window, most recently on Oct 14 when ARQT moved ahead of BAC.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
4 bullish / 1 bearish / 2 neutral, conflicted
Only ARQT
- Golden Cross Active — bullish, trend, long horizon (8.51%)
- ADX Trend Weakening — neutral, trend, medium horizon
- ATR Expansion - Breakout Mode — neutral, volatility, short horizon (6.18%)
- Beta Spike Warning — bearish, risk_regime, long horizon
- Price Reclaimed 50-Day MA — bullish, trend, medium horizon
- Uptrend Structure Active — bullish, trend, long horizon
2 bullish / 2 bearish / 1 neutral, conflicted
Only BAC
- Bollinger Band Squeeze — neutral, volatility, short horizon (4.5%)
- Death Cross Active — bearish, trend, long horizon (1.45%)
- Downtrend Structure Active — bearish, trend, long horizon
- MACD Histogram Expanding Bullish — bullish, momentum, short horizon
Both carry 1 more signal that do not separate them: OBV Bullish Divergence.
ARQT leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Price is up while the AIQ Score moved down 1 points over the same session — price and model disagree (price +2.65%, AIQ -1 points).
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +1.01%, AIQ 0 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1BAC closes the Momentum gap — currently 39 points behind, the largest single contributor to ARQT's edge.
- 2BAC's Death Cross Active resolves — a bearish trend rule currently active against it.
- 3ARQT's conflicting signal state resolves bearish — it currently carries 4 bullish and 1 bearish rules at once.
- 4A market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
ARQT leads on balance| Metric | ARQT | BAC |
|---|---|---|
| Revenue growth (YoY) | 10.8% | -3.3% |
| EPS growth (YoY) | -36.4% | -23.8% |
| Gross margin | 91.2% | 60.4% |
| Operating margin | 6.9% | 22.4% |
| Return on equity (TTM) | 3.6% | 2.3% |
| Debt to equity | 0.47 | 1.28 |
Performance
ARQT leads 5 of 6 windows| Metric | ARQT | BAC |
|---|---|---|
| 1 week (5 sessions) | 10.6% | 3.2% |
| 1 month (20 sessions) | -1.9% | -0.4% |
| 3 months (63 sessions) | 10.3% | -20.1% |
| 6 months (126 sessions) | 32.6% | 2.5% |
| Year to date | -2.7% | -7.2% |
| 1 year (252 sessions) | 20.5% | -5.7% |
Technicals
ARQT has the stronger structure| Metric | ARQT | BAC |
|---|---|---|
| RSI (14) | 48.3 | 45.9 |
| ADX (14) | 24.5 | 27.2 |
| Price vs 50-day | 2.6% | -5.6% |
| Price vs 200-day | 11.4% | -7% |
| Volatility (1M, annualized) | 97.4% | 24.8% |
Risk
BAC is the more resilient| Metric | ARQT | BAC |
|---|---|---|
| Beta | 1.47 | 0.79 |
| Sharpe ratio | 0.59 | -0.22 |
| Sortino ratio | 0.85 | -0.29 |
| Max drawdown | -37.5% | -23.7% |
| Current drawdown | -17% | -21.3% |
| Annualized volatility | 56.5% | 22.4% |
| Value at risk (95%) | -4.5% | -2.6% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, ARQT or BAC?
On the Algovestiq AIQ Score, ARQT is the stronger of the two as of Nov 15, 2026, scoring 69 against BAC's 58. The edge comes from momentum and quality. BAC is not without a case — it holds the better risk resilience profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is ARQT or BAC the better buy right now?
ARQT carries the stronger systematic profile as of Nov 15, 2026, and the comparison is rated Competitive — 4 of 6 covered evidence groups agree. A Competitive rating means the two are close enough that your objective, not the score, should decide.
Why does the AIQ Score favor ARQT over BAC?
The composite weights Quality, Value, Momentum and Risk Resilience. ARQT leads Momentum by 39 points; BAC leads Risk Resilience by 37 points; ARQT leads Quality by 12 points. Where the two split, the factor with the larger weight carries the result.
Which has more analyst upside, ARQT or BAC?
Analyst price targets imply +51.3% upside for ARQT and +24.1% for BAC, so the Street currently favors ARQT. The model and the Street agree here, which is a broader base of evidence than either alone. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, ARQT or BAC?
Neither name separates on the peer-relative Value factor. The two are level on Value. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, ARQT or BAC?
Growth figures are not covered for both names. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, ARQT or BAC?
ARQT on the Momentum factor, by 39 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, ARQT or BAC?
BAC is the more resilient of the two, so the other name carries the higher downside risk. BAC on Risk Resilience, by 37 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is ARQT more profitable than BAC?
The profitability evidence is mixed: gross margin 91.2% vs 60.4%; operating margin 6.9% vs 22.4%; ttm roe 3.6% vs 2.3%. ARQT leads on two measures and BAC on one measure, and there is no single profitability composite that resolves the split — which of the two reads as "more profitable" depends on whether you weight pricing power or operating leverage.
Is ARQT's lead over BAC getting stronger or weaker?
ARQT lead: Strengthening — the AIQ differential moved from 2 to 11 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-05-27 and 2026-11-13. The lead has changed hands 5 times in that window, most recently on 2026-10-14, when ARQT moved ahead of BAC.
What would change the ARQT vs BAC verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: BAC closes the Momentum gap — currently 39 points behind, the largest single contributor to ARQT's edge; BAC's Death Cross Active resolves — a bearish trend rule currently active against it; ARQT's conflicting signal state resolves bearish — it currently carries 4 bullish and 1 bearish rules at once; a market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.
What do the current signals say about ARQT and BAC?
ARQT: 4 bullish / 1 bearish / 2 neutral, conflicted. BAC: 2 bullish / 2 bearish / 1 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on ARQT is Golden Cross Active (bullish, long horizon). On BAC it is Death Cross Active (bearish, long horizon).
Compare ARQT and BAC with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.